Trial reportBMC anesthesiology2026
Dexmedetomidine as adjuvant of transversus abdominal plane block for cesarean delivery under multimodal analgesia: a randomized clinical trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05700045 (Effect of Dexmedetomidine Combined With Ropivacaine Transverse Abdominal Plane Block), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dexmedetomidine Combined With Ropivacaine Transverse Abdominal Plane Block (TAP) on Opioid Dosage After Cesarean Section Under Multimodal Analgesia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe parturients who have undergone cesarean delivery (CD) often suffer moderate to severe pain. Multimodal analgesia has been implemented to improve postoperative pain management following CD. The role of dexmedetomidine for multimodal analgesia after CD is not well defined. This study aimed to evaluate the efficacy of dexmedetomidine combined with ropivacaine in ultrasound-guided posterior transversus abdominis plane block(TAPB)on postoperative analgesia following CD.
methodsA total of 90 parturients scheduled for CD were divided randomly into two groups: The ropivacaine group (Group R), in which parturients were administered bilateral 0.25% ropivacaine 20 ml in posterior TAPB, and the dexmedetomidine group (Group RD), in which parturients were administered bilateral 0.25% ropivacaine and 0.5 µg/kg dexmedetomidine in posterior TAPB. Oral acetaminophen and celecoxib were routinely administered during the postoperative 48 h according to the multimodal analgesia protocol. The primary outcome was opioid consumption during the first 48 postoperative hours, and the secondary outcomes included opioid consumption during the postoperative 0-4,4–12,12–24,24–48 h, pain scores at 4,24,48 h, and time to first opioid administration.
resultsOpioid consumption (morphine equivalents, MEQ) in the postoperative 48 h showed no significant difference in Group R and Group RD (median, 12.54 mg MEQ vs. 13.86 mg MEQ), p = 0.853. The 4 hours’ postoperative opioid consumption (MEQ) (median) was significantly lower in Group RD (median, 0 mg) for Group R (median, 1.32 mg, p = 0.012). Time to first opioid request was significantly prolonged in Group RD, p = 0.002. There was no significant difference in Numerical rating scale (NRS) score at rest and movement between the two groups. But the NRS score at uterine contraction was significantly lower in Group RD than Group R, p = 0.008.
conclusionDexmedetomidine as adjuvant of posterior bilateral TAPB in parturients under multimodal analgesia did not decrease the consumption of opioids, but prolonged time to first opioid request and decreased the NRS score at uterine contraction. TRIAL REGISTRATION NUMBER: NCT05700045(the registration date: December 26,2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.